Gemtuzumab ozogamicin
- Generic Name
- Gemtuzumab ozogamicin
- Brand Names
- Mylotarg
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 220578-59-6
- Unique Ingredient Identifier
- 8GZG754X6M
- Background
Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody . The antibody ...
- Indication
Indicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial tr...
- Associated Conditions
- Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML)
- Associated Therapies
- -
Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT00577694
- Locations
- πΊπΈ
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 78
- Registration Number
- NCT00551460
- Locations
- πΊπΈ
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
πΊπΈSletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
πΊπΈSaint Louis University Cancer Center, Saint Louis, Missouri, United States
NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 250
- Registration Number
- NCT00476541
- Locations
- π©π°
Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
π©π°Rigshospitalet, Copenhagen, Denmark
Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation
- Conditions
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2007-04-16
- Lead Sponsor
- University Hospital Carl Gustav Carus
- Target Recruit Count
- 30
- Registration Number
- NCT00460447
- Locations
- π©πͺ
Medizinische Klinik und Poliklinik I, Dresden, Germany
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
- Conditions
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- The University of New South Wales
- Target Recruit Count
- 2000
- Registration Number
- NCT00454480
- Locations
- π¬π§
Queen's Hospital, Burton-upon-Trent, England, United Kingdom
π¬π§Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom
π¬π§Hereford Hospitals, Hereford, United Kingdom
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
- Conditions
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 78
- Registration Number
- NCT00413166
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1070
- Registration Number
- NCT00372593
- Locations
- πΊπΈ
University of Illinois Cancer Center, Chicago, Illinois, United States
πΊπΈChildrens Hospital Los Angeles, Los Angeles, California, United States
πΊπΈArkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT00274781
- Locations
- πΊπΈ
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Kanisa Pharmaceuticals
- Target Recruit Count
- 55
- Registration Number
- NCT00233909
Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2010-08-12
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 95
- Registration Number
- NCT00143975
- Locations
- π¦πΉ
St. Johann Hospital, Clinical Center of Salzburg, Salzburg, Austria
π©πͺDepartment of Hematology, Hemostaseology and Oncology, Medizinische Hochschule Hannover, Hannover, Germany
π©πͺMedical Department II, City Hospital Karlsruhe gGmbH, Karlsruhe, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.